WO2004047873A2 - Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses - Google Patents
Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses Download PDFInfo
- Publication number
- WO2004047873A2 WO2004047873A2 PCT/US2003/033644 US0333644W WO2004047873A2 WO 2004047873 A2 WO2004047873 A2 WO 2004047873A2 US 0333644 W US0333644 W US 0333644W WO 2004047873 A2 WO2004047873 A2 WO 2004047873A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- carbon dioxide
- polymeric material
- densified carbon
- dioxide composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
Definitions
- the present invention relates generally to medical devices and, more particularly, to methods of providing biocompatible medical devices.
- Stents are typically used as adjuncts to percutaneous transluminal balloon angioplasty procedures, in the treatment of occluded or partially occluded arteries and other blood vessels.
- a guiding catheter or sheath is percutaneously introduced into the cardiovascular system of a patient through the femoral arteries and advanced through the vasculature until the distal end of the guiding catheter is positioned at a point proximal to the lesion site.
- a guidewire and a dilatation catheter having a balloon on the distal end are introduced through the guiding catheter with the
- the guidewire is first advanced out of the guiding catheter into the patient's vasculature and is directed across the arterial lesion.
- the dilatation catheter is subsequently advanced over the previously advanced guidewire until the dilatation balloon is properly positioned across the arterial lesion.
- the expandable balloon is inflated to a predetermined size with a radiopague liquid at relatively high pressure to radially compress the atherosclerotic plaque of the lesion against the inside of the artery wall and thereby dilate the lumen of the artery.
- the balloon is then deflated to a small profile so that the dilatation catheter can be withdrawn from the patient's vasculature and blood flow resumed through the dilated artery.
- Balloon angioplasty sometimes results in short or long term failure (restenosis) . That is, vessels may abruptly close shortly after the procedure or restenosis may occur gradually over a period of months thereafter.
- implantable intraluminal prostheses commonly referred to as stents, are used to achieve long term vessel patency.
- a stent functions as scaffolding to structurally support the vessel wall and thereby maintain luminal patency, and are transported to a lesion site by means of a delivery catheter.
- Types of stents may include balloon expandable stents, spring-like, self-expandable stents, and thermally expandable stents.
- Balloon expandable stents are delivered by a dilitation catheter and are plastically deformed by an expandable member, such as an inflation balloon, from a small initial diameter to a larger expanded diameter.
- Self-expanding stents are formed as spring elements which are radially compressible about a delivery catheter. A compressed self-expanding stent is typically held in the compressed state by a delivery sheath. Upon delivery to a lesion site, the delivery sheath is retracted allowing the stent to expand.
- Thermally expandable stents are formed from shape memory alloys which have the ability to expand from a small initial diameter to a second larger diameter upon the application of heat to the alloy.
- Polymeric materials are increasingly being utilized in intraluminal prostheses, such as stents, as well as in other types of medical devices used within the bodies of subjects.
- Polymeric materials conventionally utilized in the medical device industry for implantation within the bodies of subjects include, but are not limited to polyurethanes, polyolefins ⁇ e . g. , polyethylene and polypropylene), poly ( eth) acrylates, polyesters ⁇ e . g. , polyethyleneterephthalate) , polyamides, polyvinyl resins, silicon resins ⁇ e . g. , silicone rubbers and polysiloxanes) , polycarbonates, polyfluoro ⁇ arbon resins, synthetic resins, and polystyrene.
- Many conventional polymeric materials contain a range of additives ⁇ e . g. , plasticizers, antioxidants, UV stabilizers, etc.) as well as a host of contaminants ⁇ e . g. , residual monomer, oligomers, solvent residues, catalysts, initiators, etc.).
- casting solvents such as dimethyl sulfoxide (DMSO) , chloro- organics, aromatics, tetrahydrofuran (THF) , etc. are conventionally utilized in stent production.
- various toxic organic solvents and plasticizers are conventionally used to impregnate the polymeric material of implantable devices, such as intraluminal prostheses, with pharmacological agents. Trace quantities of these materials may remain in the polymeric materials during fabrication of these devices and patients receiving these devices, or pharmacological agents eluted therefrom, may be exposed to these potentially toxic materials, particularly when the implantable device erodes.
- Fig. 1 is a flowchart of operations for impregnating polymeric material with pharmacological agents, according to embodiments of the present invention.
- biocompatible is intended to denote a material that upon contact with a living element such as a cell or tissue, does not cause toxicity.
- eluting is used herein to mean the release of a pharmacological agent from a polymeric material. Eluting may also refer to the release of a material from a substrate via diffusional mechanisms or by release from a polymeric material/substrate as a result of the breakdown or erosion of the material/substrate .
- electrode refers to the ability of a material to maintain its structural integrity for a desired period of time, and thereafter gradually undergo any of numerous processes whereby the material substantially loses tensile strength and mass. Examples of such processes comprise enzymatic and non- enzymatic hydrolysis, oxidation, enzymatically-assisted oxidation, and others, thus including bioresorption, dissolution, and mechanical degradation upon interaction with a physiological environment into components that the patient's tissue can absorb, metabolize, respire, and/or excrete.
- electroderodible and “degradable” are intended to be used herein interchangeably.
- hydrophobic is used herein to mean not soluble in water.
- hydrophilic is used herein to mean soluble in water.
- lumen is used herein to mean any inner open space or cavity of a body passageway.
- polymer and “polymeric material” are synonymous and are to be broadly construed to include, but not be limited to, homopolymers , copolymers, terpolymers, and the like.
- prosthesis is used herein in a broad sense to denote any type of intraluminal prosthesis or other device which is implanted in the body of a subject for some therapeutic reason or purpose including, but not limited to stents, drug delivery devices, etc.
- subject is used herein to describe both human beings and animals (e . g. , mammalian subjects) for medical, veterinary, testing and/or screening purposes .
- toxic materials is intended to include all types of foreign materials, contaminants, chemicals, physical impurities, and the like, without limitation, that may be harmful to a subject.
- phrases such as "between X and Y” and “between about X and Y” should be interpreted to include X and Y.
- phrases such as "between about X and Y” mean "between about X and about Y.”
- phrases such as "from about X to Y” mean “from about X to about Y.”
- Fig. 1 methods of producing biocompatible intraluminal prostheses (e. g. , stents, etc.), according to embodiments of the present invention are illustrated.
- Embodiments of the present invention can be employed in conjunction with a number of manufacturing processes associated with producing intraluminal prostheses including, but not limited to, extrusion, pultrusion, injection molding, etc.
- embodiments of the present invention may be utilized in batch, semicontinuous, or continuous processes.
- An intraluminal prosthesis ⁇ e . g. , a stent, drug delivery device, etc.) comprising polymeric material (e . g. , formed from polymeric material, or having a partial or complete coating of polymeric material) is ⁇ provided (Block 100) .
- the polymeric material may contain trace amounts of one or more toxic materials as a result of previous fabrication steps.
- casting solvents including, but not limited to, Organic solvents (polar or non-polar) such as DMSO, dimethyl acetimide (DMAc) , dimethyl foramide (DMF) , chloro-organics, aromatics (such as benzene, toluene, xylene, chlorobenzene) , THF, TFF, diglyac glycol, esters, etc.
- Organic solvents polar or non-polar
- DMAc dimethyl acetimide
- DMF dimethyl foramide
- chloro-organics such as benzene, toluene, xylene, chlorobenzene
- THF TFF
- diglyac glycol, esters, etc. diglyac glycol, esters, etc.
- unpolymerized monomers, olig ⁇ mers, polymerization initiators, catalysts, etc. may be present, as would be understood by one skilled in the art.
- Oligomers are undesired, low molecular weight
- levels of toxic materials can be reduced to predetermined, acceptable values in parts per million (ppm) based upon specific toxic materials.
- toxic material "A" that is present in the polymeric material of an intraluminal prosthesis at levels of from greater than 200, 400, 600, 800 or 1,000 pp may be reduced to "acceptable” values of, for example, 20, 50, 100, 200, or 400 ppm, etc.
- Exemplary polymeric materials that may be utilized in intraluminal prostheses include, but are not limited to, polyurethanes, polyolefin ⁇ , pol (meth) acrylates, polyesters, polyamides, polyvinyl resins, silicon resins, polycarbonates, polyfluorocarbon resins, synthetic resins, and polystyrene.
- polymeric material of intraluminal prostheses may be erodible (or an intraluminal prosthesis may have an erodible coating) or non-erodible (or an intraluminal prosthesis may have a non-erodible coating) .
- Intraluminal prostheses according to embodiments of the present invention may be formed from various materials.
- intraluminal prostheses having polymeric coatings may be metallic prostheses or polymeric prostheses.
- Exemplary erodible materials that may be utilized in intraluminal prostheses include, but are not limited to, surgical gut, silk, cotton, liposomes, poly (hydroxybutyrate) , polycarbonates, polyacrylates, polyanhydrides , polyethylene glycol, poly(ortho esters), poly (phosphoesters) , polyesters, polyamides (such as polyamides derived from D-glucose) , polyphosphazenes, poly (p-dioxane) , poly(amino acid), polyglactin, and copolymers thereof, erodible hydrogels, natural polymers such as collagen and chitosan, etc.
- erodible polymers include, but are not limited to, aliphatic polyester polymers such as poly(lactic acid), poly (L-lactic acid), poly (D,L-lactic acid), poly (glycolic acid), poly(D- lactic-co-glycolic acid), poly (L-lactic-co-glycolic acid), poly (D, L-lactic-co-gly ⁇ olic acid), poly(e- caprolactone) , poly (valerolactone) , poly(hydroxy butyrate) (including poly(hydroxy butyrate valerate) ) , poly (hydrovalerate) , polydioxanone, poly (propylene fumarate) , etc., including copolymers thereof such as polylactic acid-polyethylene glycol block copolymer, and poly (ethyleneoxide) -poly (butylenetetraphthalate) ,
- the molecular weight (that is, average molecular weight) of the polymer may be from 1,000, 10,000, 100,000 or 500,000 to 2,000,000 or 4,000,000 Daltons, or more.
- Exemplary non erodible materials that may be utilized in intraluminal prostheses (and in accordance with embodiments of the present invention) include, but are not limited to, fluoropolymers, polyesters, PET, polyethylenes, polypropylenes, etc., and/or ceramics, such as hydroxyapetite .
- intraluminal prostheses may include various pharmacological agents.
- pharmacological agents suitable for inclusion in prosthesis materials and/or coatings include, but are not limited to, drugs and other biologically active materials, and may be intended to perform a variety of functions, including, but not limited to: anti-cancer treatment ⁇ e . g. , Resan) , anti-clotting or anti-platelet formation, the prevention of smooth muscle cell growth, migration, proliferation within a vessel wall.
- Pharmacological agents may include antineoplastics, antimitotics, antiinflammatories, antiplatelets, anticoagulants, antifibrins, antithrombins, antiproliferatives, antibiotics, antioxidants, and antiallergic substances as well as combinations thereof.
- antineoplastics and/or antimitotics include paclitaxel (cytostatic and ant-inflammatory) and it's analogs and all compounds in the TAXOL® (Bristol-Myers Squibb Co., Stamford, Conn.) family of pharmaceuticals, docetaxel (e.g., TAXOTERE® from Aventis S.
- antiinflammatories include Sirolimus and it's analogs (including but not limited to Everolimus and all compounds in the Limus family of pharmaceuticals) , glucocorticoids such as dexamethasone, methylprednisolone, hydrocortisone and betamethasone and non-steroidal antiinflammatories such as aspirin, indomethacin and ibuprofen.
- antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe- pro-arg-chloromethylketone (synthetic antithrombin) , dipyridamole, glycoprotein Ilb/IIla platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as AngiomaxTM (Biogen, Inc., Cambridge, Mass.)
- cytostatic or antiproliferative agents or proliferation inhibitors include everolimus, actinomycin D, as well as derivatives and analogs thereof (manufactured by Sigma-Aldrich, Milwaukee, is.; or COSMEGEN® available from Merck & Co., Inc., Whitehouse Station, N.J.), angiop
- cilazapril or lisinopril e.g., Prinivilo and PRINZIDE® from Merck & Co., Inc., Whitehouse Station, N.J.
- calcium channel blockers such as nifedipine
- FGF fibroblast growth factor
- fish oil omega 3-fatty acid
- histamine antagonists such as lovastatin (an inhibitor of HMG- CoA reductase, a cholesterol lowering drug, brand name MEVACOR® from Merck & Co., Inc., Whitehouse Station, N.J.)
- monoclonal antibodies such as those specific for Platelet-Derived Growth Factor (PDGF) receptors) , nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thiopro
- PDGF Platelet-Derived Growth Factor
- an antiallergic agent is permirolast potassium.
- Other therapeutic substances or agents that may be used include alphainterferon, genetically engineered epithelial cells, and dexamethasone .
- U.S. Patent Nos . 4,994,033 to Shockey et al . ; 5,674,192 to Sahatian et al . and 5,545,208 to Wolff et al . disclose catheters comprising absorbable/ biodegradable polymers or hydrogels containing the desired dosage of a drug. Stents incorporating drug delivery may be found, for example, in U.S. Patent Nos.
- the polymeric material of an intraluminal prosthesis is immersed in a densified (e.g., liquid or supercritical) carbon dioxide composition for a time sufficient, and under controlled conditions, to cause the trace amounts of toxic materials to be absorbed by the densified carbon dioxide composition (Block 110) .
- a densified carbon dioxide composition e.g., liquid or supercritical
- Carbon dioxide is non-toxic, non-flammable, chemically inert, completely recoverable, abundant and inexpensive. Carbon dioxide has properties that are between those of many liquids and gases. At room temperature and above its vapor pressure, carbon dioxide exists as a liquid with a density comparable to organic solvents but with excellent wetting properties and a very low viscosity.
- carbon dioxide Above its critical temperature and pressure (31°C and 73.8 bar), carbon dioxide is in the supercritical state and has gas-like viscosities and liquid-like densities. Small changes in temperature or pressure cause dramatic changes in the density, viscosity, and dielectric properties of supercritical carbon dioxide, making it an unusually tunable, versatile, and selective solvent.
- the densified carbon dioxide composition may be heterogeneous or homogeneous in composition, i.e., may be a single phase composition or contain one or more additional phases, such as in the form of a microemulsion, emulsion, dispersion, suspension, etc.
- the densified carbon dioxide composition may comprise, consist of, or consist essentially of carbon dioxide. Where multiple phases are ' found in the densified carbon dioxide composition, the carbon dioxide may be in the continuous phase.
- One or more other ingredients may be included in the densified carbon dioxide composition, such as co- solvents (i.e., _water or organic co-solvents ' such as ethanol and methanol) , surfactants or the like may be included.
- organic c ⁇ -solvents are included, it or they may be polar or nonpolar (or at least one of each) .
- surfactants are included it or they may comprise a carbon dioxide-philic group coupled to either a lipophilic or hydrophilic group, a conventional surfactant comprising a liphophilic group coupled to a hydrophilic group, or one or more of each.
- the densified carbon dioxide composition may comprise at least 30, 40, 50, 60, 70, 80 or 90 percent by weight of carbon dioxide .
- water When water is present in the densified carbon dioxide composition, the water may comprise from about 0.01, 0.1, or 0.5 to about 1, 5, 10 or 20 percent by weight of the composition, or more.
- Immersing the polymeric material of the intraluminal prosthesis in the densified carbon dioxide composition under controlled conditions includes, but is not limited to, controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern-, temperature, rate of temperature change, pressure, rate of pressure change, composition quantity, etc. Changes in one or more of these parameters (also referred to as "tuning" the densified carbon dioxide composition) can be made to selectively absorb trace amounts of toxic materials . Moreover, changes in one or more of these parameters can control both the effectiveness and efficiency of toxic material removal.
- the densified carbon dioxide composition containing the toxic materials is removed from contact with the polymeric material (Block 120) . Removal may include complete removal or partial removal.
- the density of the removed densified carbon dioxide composition is lowered such that the trace amounts of toxic materials entrained therein become separated therefrom (Block 130) .
- the separated toxic materials are then disposed of (Block 140) .
- the density of the removed densified carbon dioxide composition may be lowered by reducing pressure and/or increasing temperature, as would be understood by one skilled in the art .
- Embodiments of the present invention described above with respect to Fig. 1 may be carried out using apparatus known to those skilled in the art.
- Immersing the polymeric material of an intraluminal prosthesis in a densified carbon dioxide composition for a time sufficient may be performed within an enclosed chamber (e.g., pressure vessel).
- Lowering the density of the densified carbon dioxide composition may also be performed within an enclosed chamber, for example an enclosed chamber separate from a chamber within which the polymeric material is immersed in the densified carbon dioxide composition.
- selective removal of toxic or other materials may be accomplished via any of a variety of known masking techniques.
- a mask may be applied to one or more portions of an intraluminal prosthesis such that toxic materials are removed only from non-masked portions of the polymeric material .
- Masking techniques are well understood by those skilled in the art and need not be described further herein.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005510351A JP4617258B2 (en) | 2002-11-14 | 2003-10-23 | Method for producing biocompatible stent for use in the body of a subject |
EP03776520A EP1560489A4 (en) | 2002-11-14 | 2003-10-23 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
AU2003284338A AU2003284338B2 (en) | 2002-11-14 | 2003-10-23 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
CA2498180A CA2498180C (en) | 2002-11-14 | 2003-10-23 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42612602P | 2002-11-14 | 2002-11-14 | |
US60/426,126 | 2002-11-14 | ||
US10/662,621 | 2003-09-15 | ||
US10/662,621 US7285287B2 (en) | 2002-11-14 | 2003-09-15 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004047873A2 true WO2004047873A2 (en) | 2004-06-10 |
WO2004047873A3 WO2004047873A3 (en) | 2004-11-18 |
Family
ID=32302669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/033644 WO2004047873A2 (en) | 2002-11-14 | 2003-10-23 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
Country Status (6)
Country | Link |
---|---|
US (1) | US7285287B2 (en) |
EP (1) | EP1560489A4 (en) |
JP (1) | JP4617258B2 (en) |
AU (1) | AU2003284338B2 (en) |
CA (1) | CA2498180C (en) |
WO (1) | WO2004047873A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU716005B2 (en) * | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US7065779B1 (en) * | 1999-10-13 | 2006-06-20 | Cisco Technology, Inc. | Technique for synchronizing multiple access controllers at the head end of an access network |
US7660621B2 (en) | 2000-04-07 | 2010-02-09 | Medtronic, Inc. | Medical device introducer |
US7704260B2 (en) | 2002-09-17 | 2010-04-27 | Medtronic, Inc. | Low profile instrument immobilizer |
US20050182422A1 (en) | 2004-02-13 | 2005-08-18 | Schulte Gregory T. | Apparatus for securing a therapy delivery device within a burr hole and method for making same |
US7635510B2 (en) * | 2004-07-07 | 2009-12-22 | Boston Scientific Scimed, Inc. | High performance balloon catheter/component |
US20070196423A1 (en) * | 2005-11-21 | 2007-08-23 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
US8048448B2 (en) * | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
WO2008070189A2 (en) | 2006-12-06 | 2008-06-12 | The Cleveland Clinic Foundation | Method and system for treating acute heart failure by neuromodulation |
US8609769B2 (en) * | 2008-03-27 | 2013-12-17 | Mitsui Chemicals, Inc. | Resin composition and use thereof |
US8298466B1 (en) | 2008-06-27 | 2012-10-30 | Abbott Cardiovascular Systems Inc. | Method for fabricating medical devices with porous polymeric structures |
US8642063B2 (en) * | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
US8888840B2 (en) * | 2009-05-20 | 2014-11-18 | Boston Scientific Scimed, Inc. | Drug eluting medical implant |
EP2432425B1 (en) | 2009-05-20 | 2018-08-08 | 480 Biomedical, Inc. | Medical implant |
US9265633B2 (en) | 2009-05-20 | 2016-02-23 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
US8795309B2 (en) * | 2009-07-29 | 2014-08-05 | Smiths Medical Asd, Inc. | Device for insertion of a cannula of an infusion device and method |
US8372133B2 (en) | 2009-10-05 | 2013-02-12 | 480 Biomedical, Inc. | Polymeric implant delivery system |
BR112012007955B1 (en) * | 2009-10-06 | 2020-07-21 | Sahajanand Medical Technologies Private Limited | bioresorbable vascular implant |
AU2015264121B2 (en) | 2014-05-22 | 2020-05-28 | CARDIONOMIC, Inc. | Catheter and catheter system for electrical neuromodulation |
AU2015315658B2 (en) | 2014-09-08 | 2019-05-23 | CARDIONOMIC, Inc. | Catheter and electrode systems for electrical neuromodulation |
AU2015315570B2 (en) | 2014-09-08 | 2020-05-14 | CARDIONOMIC, Inc. | Methods for electrical neuromodulation of the heart |
EP3610917A1 (en) | 2015-01-05 | 2020-02-19 | Cardionomic, Inc. | Cardiac modulation facilitation methods and systems |
AU2017229496B2 (en) | 2016-03-09 | 2022-03-31 | CARDIONOMIC, Inc. | Cardiac contractility neurostimulation systems and methods |
EP3442642A1 (en) | 2016-04-12 | 2019-02-20 | Boston Scientific Scimed, Inc. | Medical balloon |
WO2018111898A1 (en) | 2016-12-13 | 2018-06-21 | Boston Scientific Scimed, Inc. | Medical balloon |
EP3615099B1 (en) | 2017-04-25 | 2023-03-01 | Boston Scientific Scimed, Inc. | Medical balloon |
EP3664703A4 (en) | 2017-09-13 | 2021-05-12 | Cardionomic, Inc. | Neurostimulation systems and methods for affecting cardiac contractility |
JP2021535776A (en) | 2018-08-13 | 2021-12-23 | カーディオノミック,インク. | Systems and methods that act on systole and / or relaxation |
JP2022531658A (en) | 2019-05-06 | 2022-07-08 | カーディオノミック,インク. | Systems and methods for noise reduction of physiological signals during electrical neural regulation |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994033A (en) | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US5443458A (en) | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5551954A (en) | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5766710A (en) | 1994-06-27 | 1998-06-16 | Advanced Cardiovascular Systems, Inc. | Biodegradable mesh and film stent |
WO1998026886A1 (en) | 1996-12-02 | 1998-06-25 | The University Of North Carolina At Chapel Hill | Use of co2-soluble materials as transient spacers, templates, adhesives, binders, coatings and molds |
WO1998051812A2 (en) | 1997-05-12 | 1998-11-19 | Metabolix, Inc. | Polyhydroxyalkanoates for in vivo applications |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US5059211A (en) | 1987-06-25 | 1991-10-22 | Duke University | Absorbable vascular stent |
US5527337A (en) | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
DE68922497T2 (en) | 1988-08-24 | 1995-09-14 | Marvin J Slepian | ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS. |
US5085629A (en) | 1988-10-06 | 1992-02-04 | Medical Engineering Corporation | Biodegradable stent |
US4975280A (en) | 1989-01-23 | 1990-12-04 | Ethyl Corporation | Bioerodable sustained release implants |
CH678393A5 (en) | 1989-01-26 | 1991-09-13 | Ulrich Prof Dr Med Sigwart | |
CA2017332A1 (en) * | 1989-06-29 | 1990-12-29 | Richard W. Greiner | Pharmaceutically impregnated catheters |
JPH077756B2 (en) * | 1989-07-26 | 1995-01-30 | 株式会社日立製作所 | Method for taking samples from supercritical gas equipment |
US6004346A (en) | 1990-02-28 | 1999-12-21 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5258020A (en) | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
AU650700B2 (en) | 1991-03-08 | 1994-06-30 | Keiji Igaki | Luminal stent, holding structure therefor and device for attaching luminal stent |
US5443498A (en) | 1991-10-01 | 1995-08-22 | Cook Incorporated | Vascular stent and method of making and implanting a vacsular stent |
USRE36370E (en) | 1992-01-13 | 1999-11-02 | Li; Shu-Tung | Resorbable vascular wound dressings |
CA2087132A1 (en) | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
EP0566245B1 (en) | 1992-03-19 | 1999-10-06 | Medtronic, Inc. | Intraluminal stent |
US5591224A (en) | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Bioelastomeric stent |
US5271400A (en) | 1992-04-01 | 1993-12-21 | General Electric Company | Tracking system to monitor the position and orientation of a device using magnetic resonance detection of a sample contained within the device |
JP3739411B2 (en) | 1992-09-08 | 2006-01-25 | 敬二 伊垣 | Vascular stent, manufacturing method thereof, and vascular stent device |
US5449382A (en) | 1992-11-04 | 1995-09-12 | Dayton; Michael P. | Minimally invasive bioactivated endoprosthesis for vessel repair |
US5340614A (en) | 1993-02-11 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Methods of polymer impregnation |
WO1994021196A2 (en) | 1993-03-18 | 1994-09-29 | C.R. Bard, Inc. | Endovascular stents |
NL9300500A (en) | 1993-03-22 | 1994-10-17 | Industrial Res Bv | Expandable hollow sleeve for locally supporting and / or strengthening a body vessel, as well as a method for manufacturing it. |
US5456917A (en) | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
US5441515A (en) | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
US5849035A (en) | 1993-04-28 | 1998-12-15 | Focal, Inc. | Methods for intraluminal photothermoforming |
US5590654A (en) | 1993-06-07 | 1997-01-07 | Prince; Martin R. | Method and apparatus for magnetic resonance imaging of arteries using a magnetic resonance contrast agent |
US5417213A (en) | 1993-06-07 | 1995-05-23 | Prince; Martin R. | Magnetic resonance arteriography with dynamic intravenous contrast agents |
US5579767A (en) | 1993-06-07 | 1996-12-03 | Prince; Martin R. | Method for imaging abdominal aorta and aortic aneurysms |
US5433500A (en) * | 1993-12-17 | 1995-07-18 | New Vision Fiberglass Inc. | Camper shell reinforcement device |
JP2703510B2 (en) | 1993-12-28 | 1998-01-26 | アドヴァンスド カーディオヴァスキュラー システムズ インコーポレーテッド | Expandable stent and method of manufacturing the same |
AU689850B2 (en) * | 1994-01-31 | 1998-04-09 | Bausch & Lomb Incorporated | Treatment of contact lenses with supercritical fluid |
US5788687A (en) | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
EP0761251B1 (en) | 1994-10-17 | 2004-12-29 | Kabushikikaisha Igaki Iryo Sekkei | Drug-releasing stent |
US5549662A (en) | 1994-11-07 | 1996-08-27 | Scimed Life Systems, Inc. | Expandable stent using sliding members |
US5607518A (en) * | 1995-02-22 | 1997-03-04 | Ciba Geigy Corporation | Methods of deblocking, extracting and cleaning polymeric articles with supercritical fluids |
AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US5591199A (en) | 1995-06-07 | 1997-01-07 | Porter; Christopher H. | Curable fiber composite stent and delivery system |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6033434A (en) | 1995-06-08 | 2000-03-07 | Ave Galway Limited | Bifurcated endovascular stent and methods for forming and placing |
US5744958A (en) | 1995-11-07 | 1998-04-28 | Iti Medical Technologies, Inc. | Instrument having ultra-thin conductive coating and method for magnetic resonance imaging of such instrument |
US5741293A (en) | 1995-11-28 | 1998-04-21 | Wijay; Bandula | Locking stent |
US5808060A (en) * | 1995-12-11 | 1998-09-15 | Cephalon, Inc. | Fused isoindolones |
US5723508A (en) | 1996-01-25 | 1998-03-03 | Northwestern University | Method of fabricating emulsion freeze-dried scaffold bodies and resulting products |
US5670161A (en) | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
US5916585A (en) | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5868781A (en) | 1996-10-22 | 1999-02-09 | Scimed Life Systems, Inc. | Locking stent |
US5917011A (en) * | 1996-11-07 | 1999-06-29 | The Penn State Research Foundation University Park | Short-cycle removal of impurities from polymers |
CA2274906A1 (en) | 1996-12-13 | 1998-06-18 | Gregory J. Delmain | Biocompatible medical devices with polyurethane surface |
US5733330A (en) | 1997-01-13 | 1998-03-31 | Advanced Cardiovascular Systems, Inc. | Balloon-expandable, crush-resistant locking stent |
CA2256323C (en) | 1997-03-31 | 2007-05-22 | Kabushikikaisha Igaki Iryo Sekkei | Stent for vessel |
US6272370B1 (en) | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
US6267769B1 (en) | 1997-05-15 | 2001-07-31 | Regents Of The Universitiy Of Minnesota | Trajectory guide method and apparatus for use in magnetic resonance and computerized tomographic scanners |
US6245103B1 (en) * | 1997-08-01 | 2001-06-12 | Schneider (Usa) Inc | Bioabsorbable self-expanding stent |
US5980564A (en) | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US6174330B1 (en) | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US5984957A (en) | 1997-08-12 | 1999-11-16 | Schneider (Usa) Inc | Radially expanded prostheses with axial diameter control |
AU8916698A (en) | 1997-08-26 | 1999-03-16 | Duke University | Radioactive stent structures |
EP1024753B1 (en) | 1997-09-26 | 2003-04-09 | Duke University | Perfusion-occlusion catheter |
US5924987A (en) | 1997-10-06 | 1999-07-20 | Meaney; James F. M. | Method and apparatus for magnetic resonance arteriography using contrast agents |
US6156062A (en) | 1997-12-03 | 2000-12-05 | Ave Connaught | Helically wrapped interlocking stent |
US5957975A (en) | 1997-12-15 | 1999-09-28 | The Cleveland Clinic Foundation | Stent having a programmed pattern of in vivo degradation |
US6001418A (en) | 1997-12-16 | 1999-12-14 | The University Of North Carolina At Chapel Hill | Spin coating method and apparatus for liquid carbon dioxide systems |
US6179867B1 (en) | 1998-01-16 | 2001-01-30 | Advanced Cardiovascular Systems, Inc. | Flexible stent and method of use |
US6224626B1 (en) | 1998-02-17 | 2001-05-01 | Md3, Inc. | Ultra-thin expandable stent |
JP3444781B2 (en) * | 1998-03-10 | 2003-09-08 | 旭化成アイミー株式会社 | Method for modifying medical polymer and medical polymer substrate |
JPH11335343A (en) * | 1998-05-26 | 1999-12-07 | Nippon Polyurethane Ind Co Ltd | Production of polyfunctional aromatic polyisocyanate |
US6139511A (en) | 1998-06-29 | 2000-10-31 | Advanced Cardiovascular Systems, Inc. | Guidewire with variable coil configuration |
JP4898991B2 (en) | 1998-08-20 | 2012-03-21 | クック メディカル テクノロジーズ エルエルシー | Sheathed medical device |
US6120847A (en) | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6312457B1 (en) | 1999-04-01 | 2001-11-06 | Boston Scientific Corporation | Intraluminal lining |
US6368346B1 (en) * | 1999-06-03 | 2002-04-09 | American Medical Systems, Inc. | Bioresorbable stent |
US6440405B1 (en) | 1999-06-07 | 2002-08-27 | University Of Delaware | Quaternary ammonium functionalized dendrimers and methods of use therefor |
WO2001004117A1 (en) | 1999-07-09 | 2001-01-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl protease inhibitors and diagnostic imaging agents |
US6302907B1 (en) | 1999-10-05 | 2001-10-16 | Scimed Life Systems, Inc. | Flexible endoluminal stent and process of manufacture |
US7226475B2 (en) * | 1999-11-09 | 2007-06-05 | Boston Scientific Scimed, Inc. | Stent with variable properties |
US6264671B1 (en) | 1999-11-15 | 2001-07-24 | Advanced Cardiovascular Systems, Inc. | Stent delivery catheter and method of use |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US6481262B2 (en) * | 1999-12-30 | 2002-11-19 | Advanced Cardiovascular Systems, Inc. | Stent crimping tool |
US6264683B1 (en) | 2000-03-17 | 2001-07-24 | Advanced Cardiovascular Systems, Inc. | Stent delivery catheter with bumpers for improved retention of balloon expandable stents |
ATE324917T1 (en) * | 2000-03-20 | 2006-06-15 | Boston Scient Ltd | SELECTIVE RADIATION OPAQUE COATING OF A STENT |
US6436132B1 (en) | 2000-03-30 | 2002-08-20 | Advanced Cardiovascular Systems, Inc. | Composite intraluminal prostheses |
AU5543801A (en) * | 2000-05-16 | 2001-11-26 | Ortho Mcneil Pharm Inc | Process for coating medical devices using super-critical carbon dioxide |
WO2002007785A2 (en) * | 2000-07-20 | 2002-01-31 | Sulzer Carbomedics Inc. | Implantable biocompatible animal tissue |
JP2002035135A (en) * | 2000-07-31 | 2002-02-05 | Manii Kk | Stent and method for manufacturing stent |
US6451373B1 (en) | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
JP4386564B2 (en) * | 2000-11-30 | 2009-12-16 | 日東電工株式会社 | Method of removing low molecular weight material from polyimide precursor or polyimide containing low molecular weight material |
US20020077691A1 (en) * | 2000-12-18 | 2002-06-20 | Advanced Cardiovascular Systems, Inc. | Ostial stent and method for deploying same |
US20030044514A1 (en) * | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
US6945994B2 (en) * | 2001-12-05 | 2005-09-20 | Boston Scientific Scimed, Inc. | Combined balloon-expanding and self-expanding stent |
-
2003
- 2003-09-15 US US10/662,621 patent/US7285287B2/en not_active Expired - Fee Related
- 2003-10-23 WO PCT/US2003/033644 patent/WO2004047873A2/en active Application Filing
- 2003-10-23 EP EP03776520A patent/EP1560489A4/en not_active Withdrawn
- 2003-10-23 JP JP2005510351A patent/JP4617258B2/en not_active Expired - Fee Related
- 2003-10-23 AU AU2003284338A patent/AU2003284338B2/en not_active Ceased
- 2003-10-23 CA CA2498180A patent/CA2498180C/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994033A (en) | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5551954A (en) | 1991-10-04 | 1996-09-03 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5769883A (en) | 1991-10-04 | 1998-06-23 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5443458A (en) | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
US5766710A (en) | 1994-06-27 | 1998-06-16 | Advanced Cardiovascular Systems, Inc. | Biodegradable mesh and film stent |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
WO1998026886A1 (en) | 1996-12-02 | 1998-06-25 | The University Of North Carolina At Chapel Hill | Use of co2-soluble materials as transient spacers, templates, adhesives, binders, coatings and molds |
WO1998051812A2 (en) | 1997-05-12 | 1998-11-19 | Metabolix, Inc. | Polyhydroxyalkanoates for in vivo applications |
Non-Patent Citations (2)
Title |
---|
KOEGLER ET AL.: "Carbon Dioxide Extraction of Residual Chloroform from Biodegradable Polymers", J BIOMED MATER RES, vol. 63, no. 5, 2002, pages 567 - 76, XP002602824, DOI: doi:10.1002/JBM.10209 |
VANDENBURG ET AL.: "Analytical Extraction of Additives from Polymers", ANALYST, vol. 122, 1997, pages 101R - 115R, XP002602825 |
Also Published As
Publication number | Publication date |
---|---|
AU2003284338B2 (en) | 2009-04-09 |
CA2498180A1 (en) | 2004-06-10 |
CA2498180C (en) | 2013-04-16 |
US7285287B2 (en) | 2007-10-23 |
US20040098120A1 (en) | 2004-05-20 |
JP4617258B2 (en) | 2011-01-19 |
JP2006506214A (en) | 2006-02-23 |
EP1560489A2 (en) | 2005-08-10 |
AU2003284338A1 (en) | 2004-06-18 |
WO2004047873A3 (en) | 2004-11-18 |
EP1560489A4 (en) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7285287B2 (en) | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses | |
AU2004220631B2 (en) | Intraluminal prostheses with annealed polymer coating | |
AU2003286631B2 (en) | Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents | |
US7005137B1 (en) | Coating for implantable medical devices | |
EP1684821B1 (en) | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same | |
EP1986711B1 (en) | Implantable medical device with surface-eroding polyester drug delivery coating | |
US20060095122A1 (en) | Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same | |
EP2676639A1 (en) | Stent delivery system | |
US20130032967A1 (en) | Cold ethylene oxide sterilization of a biodegradable polymeric stent | |
US9610387B2 (en) | Plasticizers for a biodegradable scaffolding and methods of forming same | |
WO2013043429A1 (en) | Cold ethylene oxide sterilization of a biodegradable polymeric stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003284338 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003776520 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2498180 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005510351 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003776520 Country of ref document: EP |